Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Cut to $15.00 by Analysts at Robert W. Baird

Karyopharm Therapeutics (NASDAQ:KPTI) had its price target trimmed by Robert W. Baird from $21.00 to $15.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has an outperform rating on the stock.

KPTI has been the subject of a number of other research reports. Rodman & Renshaw raised shares of Karyopharm Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 10th. The Goldman Sachs Group set a $12.00 price target on Karyopharm Therapeutics in a report on Wednesday, December 17th. Cantor Fitzgerald assumed coverage on Karyopharm Therapeutics in a research report on Thursday, February 5th. They issued an “overweight” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research note on Monday, December 29th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $12.00 price objective on shares of Karyopharm Therapeutics in a research report on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $14.86.

Karyopharm Therapeutics Stock Performance

NASDAQ KPTI opened at $5.21 on Wednesday. The company has a market capitalization of $95.55 million, a price-to-earnings ratio of -0.31 and a beta of 0.13. The company’s 50-day simple moving average is $7.76 and its two-hundred day simple moving average is $6.84. Karyopharm Therapeutics has a one year low of $3.51 and a one year high of $10.99.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Friday, February 13th. The company reported ($2.23) earnings per share for the quarter, topping the consensus estimate of ($2.26) by $0.03. The business had revenue of $34.08 million during the quarter, compared to analysts’ expectations of $33.16 million. Equities analysts expect that Karyopharm Therapeutics will post -0.71 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in KPTI. T. Rowe Price Investment Management Inc. grew its stake in shares of Karyopharm Therapeutics by 112.8% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,491,409 shares of the company’s stock worth $10,977,000 after acquiring an additional 790,417 shares during the last quarter. Ikarian Capital LLC raised its position in shares of Karyopharm Therapeutics by 1,897.9% in the 4th quarter. Ikarian Capital LLC now owns 544,554 shares of the company’s stock valued at $4,008,000 after purchasing an additional 517,297 shares during the last quarter. Boothbay Fund Management LLC purchased a new position in shares of Karyopharm Therapeutics in the 4th quarter valued at approximately $1,064,000. Walleye Capital LLC acquired a new stake in Karyopharm Therapeutics in the 4th quarter worth approximately $704,000. Finally, Geode Capital Management LLC boosted its stake in Karyopharm Therapeutics by 101.2% in the 4th quarter. Geode Capital Management LLC now owns 187,734 shares of the company’s stock worth $1,382,000 after purchasing an additional 94,445 shares in the last quarter. 66.44% of the stock is owned by institutional investors and hedge funds.

Key Karyopharm Therapeutics News

Here are the key news stories impacting Karyopharm Therapeutics this week:

• Positive Sentiment: SENTRY met the co‑primary endpoint for spleen‑volume reduction and the company reported faster and larger SVR35 responses plus a reported >50% reduction in risk of death versus ruxolitinib; Karyopharm will meet the FDA to discuss the data and potential sNDA/label expansion. PR Newswire: SENTRY met spleen endpoint
• Neutral Sentiment: Company held a scheduled conference call and trading was briefly halted for pending news as the market digested top‑line results and management commentary. Seeking Alpha: SENTRY transcript
• Neutral Sentiment: Analysts trimmed price targets but largely kept bullish ratings — Robert W. Baird cut its target to $15 (still “Outperform”) and HC Wainwright lowered its target to $8 (still “Buy”) — keeping upside expectations but at lower valuations. Benzinga: analyst updates
• Negative Sentiment: SENTRY missed its second co‑primary endpoint (symptom improvement), which raises regulatory/labeling uncertainty and contributed to sharp selling pressure in early trading. Zacks: mixed Phase III data
• Negative Sentiment: Karyopharm announced a $30M private placement with RA Capital (plus ~ $44M if warrants exercised), a dilutive financing that spurred additional selling pressure. PR Newswire: $30M private placement
• Negative Sentiment: Short interest has risen markedly (3.59M shares as of Mar 13, ~19.9% of shares), which can amplify downside momentum as the market digests ambiguous trial outcomes and dilution.
• Negative Sentiment: Market headlines captured both viewpoints — some outlets noted positive trial aspects and a 10% intraday bounce, others highlighted pre‑market slumps and larger percentage drops tied to the financing and mixed read on approval odds. Blockonomi: stock reaction to financing MSN: shares rise 10% after results

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.